Formulary Search Results for: OBINUTUZUMAB
8.2.3 Anti-lymphocyte monoclonal antibodies - View Category
Total Formulary
OBINUTUZUMAB (GAZYVARO) (infusion)
Restrictions:
Restricted to specialist use in accordance with regional protocols for the following indications:
- CLL: In combination with chlorambucil, obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) and with comorbidities making them unsuitable for full-dose fludarabine based therapy (regional protocol)
- Follicular Lyphoma: In combination with bendmustine followed by obinutuzumab maintenance is indicated for the treatment of patients with follicular lymphoma who did not respond or who progressed during or up to six months after treatment with rituximab or a rituximab-containing regimen (in development).
Prescribing Notes:
Obinutuzumab is currently non-Formulary for the following indications:
- Follicular Lymphoma: in combination with chemotherapy followed by obinutuzumab maintenance therapy in patients achieving a response, for the treatment of patients with previously untreated advanced follicular lymphoma is not recommended by SMC and remains non-formulary.